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Abstract 
Human cancer cells overexpress many peptide receptors as molecular targets. Radiolabeled 
peptides that bind with high affinity and specificity to the receptors on tumor cells hold great 
potential for both diagnostic imaging and targeted radionuclide therapy. The advantage of 
solid-phase peptide synthesis, the availability of different chelating agents and prosthetic 
groups and bioconjugation techniques permit the facile preparation of a wide variety of 
peptide-based targeting molecules with diverse biological and tumor targeting properties. 
Some of  these  peptides,  including  somatostatin,  bombesin,  vasoactive  intestinal  peptide, 
gastrin, neurotensin, exendin and RGD are currently under investigation. It is anticipated that 
in the near future many of these peptides may find applications in nuclear oncology. This ar-
ticle presents recent developments in the field of small peptides, and their applications in the 
diagnosis and treatment of cancer. 
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Introduction 
Molecular  imaging  techniques  are  increasingly 
being used in the localization of disease, the staging of 
disease  and  for  therapy  control.  The  most  sensitive 
imaging methods are those using nuclear probes for 
single  photon  emission  computed  tomography 
(SPECT) and positron emission tomography (PET). A 
variety of imaging probes have been developed for 
different molecular targets. Radiolabeled peptides are 
valuable biological tools for tumor receptor imaging 
and targeted radionuclide therapy. This attributed to 
the  favorable  pharmacokinetics  and  specific  tumor 
targeting  characteristics,  together  with  the  overex-
pression of their receptors on the tumor cells, making 
these  peptides  attractive  agents  for  imaging  and 
therapy [1-4]. Peptides primarily synthesized in the 
brain,  especially  in  neurons,  are  called  “neuropep-
tides” [2, 3]. However, since most of these peptides 
are also found in the gut, lymphatic tissue, endocrine 
system, etc., the terminology “regulatory peptide” is 
often used [3]. Some of the most important regulatory 
peptides and their receptors overexpressed on tumors 
are listed in Table 1. The action of neuropeptides is 
mediated  by  their  binding  to  specific,  mem-
brane-associated receptors. The majority of these re-
ceptors  belong  to  the  family  of  G-protein-coupled 
receptors [2]. These receptors are consisting of a single 
polypeptide  chain,  with  seven  transmembrane  do-
mains, an extracellular domain with the ligand bind-
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ing  site,  and  an  intracellular  domain  linked  to 
G-proteins and arrestin for the activation of  second 
messengers  and  internalization  [5].  These  receptors 
represent  useful  molecular  targets  for  the  detection 
and treatment of cancer because they are located on 
the plasma membrane and upon binding of the radi-
oligand, the receptor-ligand complex is internalized, 
allowing long retention of radioactivity in tumor cells 
[6]. 
 
 
Table 1. Peptide receptor expression patterns. The main 
receptor types overexpressed in human tumor cells are in 
bold. 
Peptide  
 
Receptor 
types/subtypes 
 
Tumor expression 
Somatostatin  sst1, sst2, sst3, sst4, 
sst5 
Neuroendocrine tumors (gas-
troenteropancreatic tumors), 
lymphoma, paraganglioma, 
carcinoids, breast, brain, renal, 
small cell lung cancer, me-
dullary thyroid cancer 
Bombesin/GRP BB1 (NMB-R), BB2 
(GRP-R), 
BB3, BB4 
Prostate, breast, pancreas, 
gastric, colorectal, small cell 
lung cancer 
VIP  VPAC1, VPAC2  Adenocarcinomas of breast, 
prostate, stomach and liver; 
neuroendocrine tumors 
α-M2  α-M2-R  Breast cancer 
α-MSH  MC1-5R  Melanomas 
CCK/gastrin  CCK1, CCK2  Medullary thyroid cancer, 
small cell lung cancer, gas-
trointestinal stromal tumor, 
stromal ovarian cancer, as-
trocytomas 
Neurotensin  NTR1, NTR2, NTR3  Small cell lung cancer, colon, 
exocrine ductal pancreatic 
cancer, Ewing sarcoma, men-
ingioma, astrocytoma, breast, 
prostate cancer 
LHRH  LHRH-R  Prostate, breast cancer 
Substance P 
 
NK1, NK2, NK3  Glial tumors (glioblastoma, 
medullary thyroid cancer), 
pancreas, breast, small cell 
lung cancer  
Exendin 
 
GLP-1  Insulinomas, gastrinomas, 
pheochromocytomas, para-
gangliomas and medullary 
thyroid carcinomas  
RGD   αvβ3-integrin   Glioma, breast, prostate can-
cer 
GRP, gastrin-releasing peptide; VIP, vasoactive intestinal peptide; 
α-MSH, α-melanocyte-stimulating hormone; CCK, cholecystokinin; 
LHRH, luteinizing hormone-releasing hormone; GLP, gluca-
gon-like peptide; RGD, Arg-Gly-Asp. 
 
Peptide-based  radiopharmaceuticals  were  in-
troduced into the clinic more than two decades ago [7, 
8]. The first and most successful registered imaging 
agent  to  date  is  the  somatostatin  (SST)  analog, 
111In-DTPA0-octreotide  (111In-OctreoScan,  111In-pente-
treotide) (Figure 1) [9, 10]. The Food and Drug Ad-
ministration (FDA) approved  111In-DTPA0-octreotide 
is  proven  to  be  effective  for  imaging  SST  recep-
tor-positive  lesions,  such  as  neuroendocrine  tumors 
(NETs), mammary cancer and small cell lung cancer 
[9-11]. Another important application of radiolabeled 
octreotide and other SST peptide analogs is peptide 
receptor-mediated  radionuclide  therapy  (PRRT) 
[11-14]. The thriving advent of 111In-DTPA0-octreotide 
raised  interest  in  the  development  of  radiolabeled 
peptides to target other tumor-related peptide recep-
tor systems [1, 4]. This interest resulted in the discov-
ery  of  bombesin  peptide  analogs  to  target 
bombesin/gastrin-releasing peptide receptors, which 
are overexpressed in many common human cancers 
[2,  15-18].  Other  radiolabeled  peptides,  such  as  the 
analogs of vasoactive intestinal peptide [19-21], neu-
rotensin  [22-25],  cholecystokinin/gastrin  [26-29],  ex-
endin [30-33] and RGD (Arg-Gly-Asp) [34-37], have 
been developed and are currently under preclinical or 
clinical evaluation to establish their applicability for 
the diagnosis or treatment of cancers [2, 4]. 
Because of rapid progress in the field of radio-
labeled peptides it is difficult to cover all aspects per-
taining to the subject. The focus of this article remains 
the  chief  applications  of  radiolabeled  peptides  in 
cancer  research  and  development,  with  major  em-
phasis  on  recent  development  of  small  peptides  as 
targeting agents in nuclear oncology. 
Characteristics and limitations of small ra-
diopeptides 
The  distinctive  advantages  of  small  radiopep-
tides over other biologically active molecules, such as 
proteins and antibodies, are summarized in Table 2. 
Receptors for peptides are often found in higher den-
sity on tumor cells than in normal tissues; hence spe-
cifically designed receptor-binding radiolabeled pep-
tides  could  enable  efficient  visualization  of  tumors. 
Because of their small size, peptides usually exhibit 
rapid  pharmacokinetics,  and  good  tumor  targeting 
characteristics, with the ability to penetrate into tu-
mors efficiently [1-3]. Peptides can easily be synthe-
sized using conventional peptide synthesizers and the 
desired  pharmacokinetic  characteristics  can  be  mo-
lecularly engineered (by making appropriate changes 
in the peptide sequence) during synthesis and/or by 
adding a biomodifying molecule [38, 39]. Automated 
peptide synthesizers are available for parallel synthe-Theranostics 2012, 2(5) 
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sis  procedures  allowing  the  synthesis  of  peptide  li-
braries in short time. 
Tumor  receptor  imaging  creates  distinct  chal-
lenges for the design of peptide-based radiopharma-
ceuticals and imaging approaches [40]. Most receptors 
have high affinities for their ligands and are active at 
nanomolar  concentrations  of  the  ligands.  Therefore, 
radiopharmaceutical preparations with high specific 
radioactivity are crucial. Even small molar quantities 
of imaging agents may saturate a receptor, limiting 
the  ability  to  visualize  receptor  expression  and  in-
creasing the background of nonspecific binding. For 
this reason, molecular imaging of tumor receptors has 
been  mainly  confined  to  radionuclide  imaging 
(SPECT and PET), with which it is possible to generate 
medical  images  with  micromolar  to  picomolar  con-
centrations of imaging probes [40]. It is important to 
use a minimum possible amount of a peptide in hu-
mans  to  reduce  any  adverse  pharmacologic  effects. 
For instance, it has been shown that VIP is pharma-
cologically  very  potent  peptide  molecule  and  doses 
even in the submicrogram range will produce toxic 
effects,  including  hypertension,  bronchospasm  and 
diarrhea [4], requiring efficient purification step be-
fore administration in  order to reduce the adminis-
tered dose to subpharmacologic levels.  
 
 
Figure 1. Structures of somatostatin-14 and -28 and [DTPA0-D-Phe1]octreotide (OctreoScan). Theranostics 2012, 2(5) 
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Table 2. Requirements of small peptides. 
 Small in size 
 Easy to synthesize 
 Easy to radiolabel 
 feasibility of kit formulation 
 Amenable to chemical/molecular modifications 
 Ability to attach a chelating agent at the C- or N-terminus of the 
peptide 
 High receptor binding affinity 
 High tumor penetration 
 Favorable pharmacokinetics 
 Attain a high concentration in the target tissues 
 Rapid clearance from the blood and non-target tissues 
 Rate and route of excretion can be modified 
 Few side effects 
 Not immunogenic 
 Many biologically important targets 
 
 
For smaller biomolecules, such as peptides the 
radioisotope label may significantly affect binding to 
the receptor and in vivo metabolism. In this situation, 
the choices of radionuclide, labeling position or loca-
tion of the radiolabel can be critical [40]. Radiolabeling 
at  a  specific-site  (chelation-site)  remote  from  the 
binding  region  is  important  to  prevent  the  loss  of 
binding affinity and biological activity of the radio-
labeled peptides [1, 3].  
The biologic role of most receptor systems im-
portant in cancer is derived from their role in the tis-
sue of cancer origin. In general, tumor receptors are 
expressed in the parent cell lineage and have an es-
tablished physiologic function. For example, estrogen 
receptor expression is vital to the function of normal 
mammary gland epithelial cells. Many tumor recep-
tors also play an important role in promoting carcin-
ogenesis or tumor growth, as is the case for steroid 
receptors in breast and prostate cancer. The depend-
ence  on  the  receptor  pathway  for  tumor  growth 
makes the receptor a suitable target for therapy, be-
cause interruption of the receptor-initiated signal will 
result in a cessation of tumor growth and often tumor 
cell death. Thus, knowledge of the levels of receptor 
expression, which may vary significantly in different 
types of tumors and even in different sites in the same 
tumor, is required to infer the possibility that recep-
tor-directed targeting will be effective [40].  
One major problem associated with unmodified 
linear peptides is their often short biological half-life 
due to rapid proteolysis in plasma. A short half-life in 
blood  is  a  major  obstacle  for  the  successful  in  vivo 
application  as  radiopharmaceuticals  since  they  may 
be  degraded  before  reaching  the  intended  target. 
Therefore,  most  peptides  have  to  be  modified  syn-
thetically  to  minimize  rapid  enzymatic  degradation 
[1, 41]. Great efforts have been focused on developing 
metabolically-stable peptides suitable for clinical use 
by  carrying  appropriate  molecular  modifications, 
such  as  the  use  of  more  stable  D-amino  acids  for 
L-amino acids, the use of pseudo-peptide bonds, the 
inclusion of amino alcohols and the insertion of un-
natural  amino  acids  or  amino  acid  residues  with 
modified  side-chains  without  compromising  the  re-
ceptor binding affinity and biological activity of the 
peptide [1]. It is the specific amino acid sequence of a 
peptide and usually the nature and type of particular 
amino  acid  side-chains  that  determine  resistance  to 
enzymatic degradation. For example, native SST, has 
a plasma half-life of approximately 2-3 min, but its 
molecularly  modified  synthetic  peptide  derivative, 
octreotide has a half-life of 1.5-2 h, making it suitable 
for clinical application [40]. 
Another issue related to radiolabeled peptides is 
often their high uptake and retention by the kidneys, 
which  is  of  a  concern,  particularly  for  radionuclide 
therapy  because  of  the  potential  nephrotoxicity  [14, 
42-44]. Though procedures have been developed and 
applied  successfully  in  the  clinics  to  manage  ne-
phrotoxicity that includes the infusion of a mixture of 
amino acids, such as lysine and arginine [45]; there is 
a  need  to  reduce  kidney  uptake  and/or  enhanced 
renal clearance of the radiopeptide. Recently, it has 
been shown that the use of the cytoprotective drug 
amifostine [46], and low doses of the plasma expander 
succinylated gelatin and gelatin-based gelofusine can 
inhibit  the  renal  uptake  of  radiolabeled  octreotide 
analogs [47, 48].  
Development of a peptide-based radio-
pharmaceutical 
The main steps involved in developing a radio-
labeled peptide for clinical application are as follows: 
(i)  identification  of  the  molecular  target  (receptor) 
with relevance to human disease and search for a lead 
peptide, which may be a natural or synthetic peptide, 
(ii) solid-phase peptide synthesis of a peptide or its 
analogs. In general, the design of a peptide is based on 
the structural composition of the endogenous ligand 
(natural peptide ligand), which exhibits high affinity 
for  the  corresponding  receptor  system.  The  natural 
peptide  molecule  is  often  structurally  modified  to 
produce  a  metabolically  stabilized  analog,  which 
preserves most of the biological activity and receptor 
affinity of the original peptide molecule, (iii) covalent 
attachment of a chelating agent or a prosthetic group Theranostics 2012, 2(5) 
 
http://www.thno.org 
485 
to  the  peptide  either  directly  or  through  a  link-
er/spacer  group,  (iv)  radiolabeling  that  allow  high 
labeling  efficiency  and  high  specific  activity  radio-
labeled peptide preparation, (v) in vitro characteriza-
tion, such as the binding of a radiopeptide with tumor 
cells,  determination  of  receptor  binding  affinity,  in-
ternalization  into  the  tumor  cells  and  dissociation 
from the tumor cells, (vi) in vivo evaluation to assess 
the  biological  behavior,  biokinetics  and  tumor  tar-
geting capacity of the radiolabeled peptide in animal 
models. Many aspects should be considered for fur-
ther development, such as the accumulation of radio-
labeled peptide in target and non-target tissues, the 
rate and extent of the clearance of radioactivity from 
the body, the excretory pathway and in vivo stability 
of  the  radiolabeled  peptide.  (vii)  The  radiolabeled 
peptides, which successfully passed all the preclinical 
tests, after toxicological studies and established radi-
opharmaceutical  preparation,  may  enter  clinical 
studies in humans [10]. 
From the design of a new peptide molecule until 
the use in the clinical settings is a long way and from a 
huge  number  of  developed  radiolabeled  peptides 
only few meet the criteria of a radiopharmaceutical 
for  clinical  application.  Thus,  in  the  drug  develop-
ment process, considerable preclinical work and the 
need  for  validation  at  each  step  of  development  is 
require in order to transfer a drug from the laboratory 
bench to the clinical bedside and ultimately obtaining 
the regulatory approval (see Figure S1/Scheme 1). As 
mentioned above, several characteristics are desirable 
when developing a molecularly engineered peptide to 
be used as a tumor imaging agent: it must bind with 
high affinity to the target receptor that is found pre-
dominantly on cancer cells and not on normal tissues, 
be specific for its target and not bind to the nontarget 
tissues,  be  sufficiently  stable  to  reach  the  tumor  le-
sions in an intact state, and be cleared rapidly from 
the blood and nontarget tissues in order to minimize 
the background radioactivity. 
 
 
Figure S1. (Scheme 1) Different phases of drug (peptide radiopharmaceutical) development process. Theranostics 2012, 2(5) 
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Radiolabeling of peptides 
Peptide-based targeted agents either design for 
diagnostic  imaging  or  radionuclide  therapy  involve 
the use of a radiometal. This requires that the radio-
metal  be  stably  attached  to  the  peptide  using  a  bi-
functional  chelating  agent  (BFCA).  An  important 
property of BFCA is that it chelates radiometals with 
high in vivo stability, resulting in minimal deposition 
of free radiometal in normal tissues. A wide variety of 
BFCAs and prosthetic groups have been developed in 
recent  years,  allowing  rapid  and  convenient  radio-
labeling  of  peptides  with  different  radionuclides. 
Several  clinically  relevant  radionuclides  have  been 
used for labeling bioactive peptides either for diag-
nostic imaging (99mTc, 111In, 68/66Ga, 18F, 123I, 64Cu), or 
for therapy (111In, 64/67Cu, 90Y, 177Lu, 213Bi) are listed in 
Table 3.  
 
 
Table 3. Methods for labeling peptides with different di-
agnostic and therapeutic radionuclides. 
Radionuclide  Half-life BFCA/prosthetic 
group 
Application 
 Technetium-99m 
(99mTc) 
6.02 h   MAG3, DADT, 
HYNIC 
diagnosis 
Fluorine-18 (18F)  1.83 h  SFB  diagnosis 
Iodine-123 (123I)  13.2 h  SIB, SIPC  diagnosis 
Gallium-68 (68Ga)  1.13 h  NOTA, DOTA  diagnosis 
Copper-64 (64Cu)  12.7 h  TETA, DOTA, 
NOTA  
diagnosis/therapy 
Indium-111 (111In)  67.2 h  DTPA, DOTA  diagnosis/therapy 
Lutetium-177 
(177Lu) 
160.8 h  DOTA  therapy 
Yttrium-90 (90Y)  64.1 h  DOTA  therapy 
Bismuth-213 
(213Bi) 
45.6 min  DOTA  therapy 
BFCA, bifunctional chelating agent; MAG3, mercaptoacetyltri-
glycine; DADT, diaminedithiol; HYNIC, 2-hydrazinonicotinic acid; 
SFB, N-succinimidyl-4-[18F]fluorobenzoate; TETA, 
1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid; SIB, 
N-succinimidyl-3-iodobenzoate; SIPC, 
N-succinimidyl-5-iodo-3-pyridinecarboxylate; DTPA, diethylene-
triaminepentaacetic acid; DOTA, 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid; NOTA, 
1,4,7-triazacyclononane-1,4,7-triacetic acid.  
 
 
Peptide radiopharmaceuticals for tumor 
imaging 
Tumor receptor imaging poses unique challeng-
es for the design and development of a peptide-based 
agent. The biological actions of the peptides are me-
diated upon binding with high affinity receptors. The 
high  overexpression  of  these  receptors  on  various 
tumor cells as compared to their low density in nor-
mal tissues has provided the molecular basis for the 
clinical use of radiolabeled peptides as tumor receptor 
imaging  and  therapeutic  agents  [40].  After  intrave-
nous  injection,  the  radiolabeled  peptide  will  extra-
vascate and bind to sites with high receptor density, 
e.g. tumor. Imaging and/or therapy follows depend-
ing on the radionuclide used. In recent years, many 
radiolabeled  peptide  analogs,  such  as  somatostatin, 
bombesin,  vasoactive  intestinal  peptide,  cholecysto-
kinin/gastrin, neurotensin, exendin and RGD deriva-
tives, have been developed for scintigraphic detection 
of  different  tumor  types  [1-4].  These  are  described 
below. 
Somatostatin peptide analogs 
Somatostatin (SST) is a naturally occurring cyclic 
disulphide-containing  peptide  with  either  14  or  28 
amino acids (Figure 1), which binds to SST receptors. 
Both natural SST-14 and SST-28 bind with high affin-
ity to five different receptor subtypes (sst15), but have 
a short plasma half-life (3 min), owing to rapid en-
zymatic  degradation  by  endogenous  peptidases, 
preventing  their  in vivo  use  [9,  49-51].  Several  syn-
thetic SST peptide analogs that are more resistant to 
enzymatic  degradation  have  been  prepared  by  mo-
lecular modifications preserving most of the biologi-
cal activity of the original SST peptide [9, 42, 49, 50]. 
Introduction of the D-amino acids, and decreasing the 
ring size to the bioactive core sequence, resulted in an 
8-amino  acid-containing  SST  analog,  “octreotide” 
(Figures  1  and  2),  that  preserves  the  4-amino  acid 
motif (Phe-D-Trp-Lys-Thr) of native SST-14 involved 
in  receptor  binding  and  has  a  significantly  longer 
plasma  half-life  as  compared  to  endogenous  SST. 
Other  SST  receptor-targeting  analogs  developed  in-
clude lanreotide and vapreotide (RC-160) (Figure 2), 
all  with  enhanced  metabolic  stability  [9,  50].  These 
analogs  preserved  the  cyclic  form  via  a  disulfide 
bond. These stabilized SST peptide analogs have dif-
ferent binding profiles for SST receptor subtypes, but 
all  show  high  affinity  for  sst2,  which  is  the  most 
prominent SST receptor on human tumors [2, 52, 53].  
Somatostatin receptors have been identified on 
the surface of many NETs and represent a valid target 
for  in  vivo  tumor  imaging  [2,  55].  SPECT  and 
PET-based agents have been applied successfully to 
image  and  quantify  the  uptake  of  receptor-specific 
radiopeptides  in  SST  receptor-positive  tumors  for 
cancer  staging,  treatment  planning  as  well  as  fol-
low-up response to therapy. Also, SST receptor bind-
ing peptides allows the detection of small metastatic Theranostics 2012, 2(5) 
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sites, which underline the importance and strength of 
molecular imaging in nuclear oncology [55]. In addi-
tion to its usefulness as a diagnostic imaging agent, 
non-radioactive SST peptide analogs have been used 
for  symptomatic  treatment  of  hormone-secreting 
NETs [2, 11, 42]. It has been shown that SST peptide 
analogs reduce the symptoms associated with excess 
hormone  secretion  and  may  also  have  direct  anti-
tumor effects [11, 40]. Several SST-derived peptides 
labeled with radiohalogens, such as 18F via prosthetic 
groups, or linked to the chelating agents to facilitate 
labeling  with  radiometals,  such  as  99mTc,  111In,  64Cu 
and 67/68Ga have been used for in vivo imaging of SST 
receptor-expressing  tumors.  When  labeled  with 
β-emitters  (90Y  or  177Lu),  these  SST  peptide  analogs 
can  be  utilized  for  receptor-mediated  radionuclide 
therapy [1, 11-14]. A few of SST peptide analogs are 
summarized in Table 4.  
 
Figure 2. Structures of DOTA-coupled somatostatin analogs. Theranostics 2012, 2(5) 
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Table 4. Radiolabeled somatostatin analogs under preclinical/clinical evaluation. 
Peptide   Major application  Reference 
Gluc/Cel-S- Dpr([18F]FBOA)TOCA   Targeting of sstr-positive AR42J tumor in mice  [114] 
64Cu-CB-TE2A-Y3-TATE   microPET imaging of sstr-positive AR42J tumor in rats   [115] 
(DOTA0),1-Nal3,Thr8]-octreotide 
(111In-DOTA-NOC-ATE)/ 
[DOTA0,BzThi3,Thr8]-octreotide 
(111In-DOTA-BOC-ATE) 
 Targeting of sstr-expressing tumors in AR4-2J tumor- bearing rats  [116] 
99mTc-EDDA/HYNIC-TOC 
(99mTc-TOC) 
 Diagnostic imaging of sstr-positive tumors in patients   [117] 
99mTc-EDDA/HYNIC-octreotate   - Imaging of sstr-expressing carcinoid tumors in patients  [118] 
Nα-(1-deoxy-D-fructosyl)-N
-(2-[18F]fluoropropionyl)-Lys0-
Tyr3-octreotate 
(Glu-Lys([18F] FP)-TOCA) 
 PET imaging of sstr-expressing tumors in patients  [119] 
[18F]FP-Glu-TOCA   PET imaging of sstr-positive tumors in patient with  
 metastatic carcinoid in the liver 
[120] 
68Ga-DOTA-D-Phe1-Tyr3-octreotide  
 (68Ga-DOTA-TOC) 
 PET imaging of sstr-positive meningioma tumors in  
 Patients  
[121] 
[DOTA]-1-Nal3-octreotide 
(68Ga-DOTA-NOC) 
 PET imaging of sstr (subtypes 2 and 5) expressing tumors in pa-
tients 
[122] 
111In-DOTA-TATE   Imaging of sstr-positive tumors in patients  [123] 
[111In-DOTA]-lanreotide 
(111In-DOTA-LAN) 
 Detection of sstr-expressing tumors in patients  [124] 
Maltotriose-[123I] Tyr3-octreotate ([123I]Mtr-TOCA)   Scintigraphic detection of sstr-positive tumors in  
 patients 
[125] 
sstr, somatostatin receptor; Glu, glucose; Cel, cellobiose; CB-TE2A, cross-bridged-tetraazamacrocycle 
4,11-bis(carboxymethyl)-1,4,8,11-tetraazabicyclo [6.6.2]hexadecane; BzThi, benzothienyl-Ala. 99mTc-TOC, 
99mTc-hydrazinonicotinyl-Tyr3-octreotide; EDDA, ethylenediamine-N,N'-diacetic acid; [18F]FP-Gluc-TOCA, 
N
-(1-deoxy-D-fructosyl)-Nε-(2-[18F]fluoropropionyl)-Lys0-Tyr3-octreotate. 
 
There are a number of factors that usually de-
termine  the  tumor  uptake  capacity  of  radiolabeled 
SST peptide analogs. These include: (i) high specific 
radioactivity preparation of the radioligand, (ii) the in 
vivo stability of the radioligand, (iii) the density of SST 
receptor-expression  in  the  tumor,  (iv)  the 
type/subtype of SST receptors expression by the tu-
mor,  (v)  the  receptor  binding  affinity  of  the  radio-
labeled  SST  analog  for  the  particular  SST  receptor 
type, (vi) the efficiency of SST receptor-mediated in-
ternalization and recycling of radiopeptide, (vii) the 
final trapping of the radiolabeled SST peptide analog 
within tumor cells, and (viii) the amount of the pep-
tide administered [5, 11, 54].  
It is worth mentioning here that common to all 
receptors is the interaction of a ligand and the recep-
tor, in which specific binding of the ligand to the re-
ceptor results in downstream biochemical or physio-
logic  changes.  Ligands  that  cause  physiological 
changes with receptor binding, typically the naturally 
occurring ligands, are called “agonists”. Ligands that 
bind to the receptor and block the binding of agonists 
but that do not activate changes are known as “an-
tagonists” [40]. It is generally believed that receptor 
agonist radioligands are more suited for tumor tar-
geting as they exhibit good receptor-mediated inter-
nalization  into  the  tumor  cell  upon  binding  to  the 
respective cell-surface receptors, thus promoting ac-
tive accumulation in the target results in optimal vis-
ualization [3]. Interestingly, however, a recent study 
performed  with  two  potent  SST  receptor-selective 
antagonists  demonstrated  that  the  high-affinity  SST 
receptor antagonists that poorly internalized into tu-
mor cells, can also be effective in terms of in vivo tu-
mor uptake characteristics in animal models as com-
pared  to  the  corresponding  agonists,  which  highly 
internalized into tumor cells. This observation which 
was made both for sst2 and sst3-selective SST peptide 
analogs, demonstrates that the SST receptor antago-
nists are preferable to SST receptor agonists for in vivo 
tumor  targeting  [56].  In  another  recent  study, 
64Cu-CB-TE2A-sst2-ANT, a SST antagonist was eval-
uated for in vivo PET imaging of sst2-positive tumors 
and  compared  to  64Cu-CB-TE2A-TATE  [57].  The 
pharmacokinetic  characteristics  indicated  the  slight 
superiority of the radioantagonists over receptor ag-
onists.  
The most recent study on the newly developed Theranostics 2012, 2(5) 
 
http://www.thno.org 
489 
sst2-antagonist, namely LM3, demonstrated high and 
persistent tumor uptake of radiolabeled SST antago-
nists. Also, profound influence of the chelator and the 
radiometal was observed on the receptor binding af-
finity  of  the  radiolabeled  conjugates  [58].  The  first 
clinical study of SST antagonists confirmed the pre-
clinical data as it showed higher tumor uptake of the 
antagonist  111In-DOTA-sst2-ANT  compared  to  the 
agonist  111In-DTPA0-octreotide  and  improved  tu-
mor-to-background  contrast,  in  particular  tu-
mor-to-kidney [59]. 
Bombesin peptide analogs 
Bombesin  (BN),  an  amphibian  14-amino  acid 
peptide (Figure 3), is a homolog of the 27-amino acid 
mammalian  gastrin-releasing  peptide  (GRP)  (Figure 
3).  Bombesin  and  GRP  share  a  highly  conserved 
7-amino  acid  C-terminal  sequence 
(Trp-Ala-Val-Gly-His-Leu-Met-NH2),  which  is  re-
quired  for  immunogenicity  and  for  high-affinity 
binding to the BN/GRP-preferring receptor [1, 2, 60]. 
Both BN and GRP show high affinity binding to the 
human  GRP  receptor,  which  is  overexpressed  by  a 
variety of cancers, including prostate, breast, gastro-
intestinal and small cell lung cancer [2, 15, 16]. The BN 
receptor  family  comprises  four  subtypes  of 
G-protein-coupled receptors, including the neurome-
din B (NMB) receptor (BB1), the GRP receptor (BB2), 
the orphan receptor (BB3), and the amphibian recep-
tor (BB4) [2, 15, 16]. Following activation of these re-
ceptors, BN and GRP possess a variety of physiologi-
cal and pharmacological functions and also play an 
important role in stimulating the growth of different 
types of cancers [2]. Of the four receptors, three re-
ceptor subtypes (BB1, BB2, and BB3) have shown to be 
expressed in variable degrees on various cancers. Of 
particular interest is the GRP receptor (BB2) that has 
been found to be overexpressed in a variety of tumors, 
including lung, breast, GIST, brain and prostate [2, 15, 
16], and hence is an attractive target for the detection 
and treatment of these cancers. Radiolabeled BN-like 
peptides, which bind to BN/GRP receptors with high 
affinity and specificity, have potential to be used for 
site-directed diagnostic and/or therapeutic purposes 
[1,  3,  4].  A  recent  study  with  68Ga-labeled 
Pan-bombesin  analog,  DOTA-PEG2-[D-Tyr6,  β-Ala11, 
Thi13,  Nle14]  BN(6-14)amide  (68Ga-BZH3),  was  per-
formed on patients with gastrointestinal stromal tu-
mors in order to determine the impact of peptide re-
ceptor scintigraphy on the diagnosis and the potential 
therapy [17]. Also in vivo kinetics of the BN peptide 
was compared with 18F-fluorodeoxyglucose (18F-FDG) 
on  the  same  patients.  The  study  demonstrates  that 
68Ga-BZH3 showed poor tumor targeting potential as 
compared  to  18F-FDG.  Further  studies  on  larger 
number of patients are required to determine the real 
potential  of  68Ga-BZH3  for  targeting  BN  recep-
tor-expressing tumors. 
 
Figure 3. Amino acid sequences of gastrin-releasing peptide, bombesin-14, vasoactive intestinal peptide, cholecystokinin and neurotensin. Theranostics 2012, 2(5) 
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One  major  problem  that  often  associated  with 
BN-like peptides is their tendency to accumulate in 
the  liver  and  intestines  due  to  high  hepatobiliary 
clearance  despite  their  hydrophilic  nature,  making 
scintigraphic  exploration  of  the  abdominal  area 
problematic [6]. The presence of GRP receptor in gas-
trointestinal  tissues  might  be  responsible  for  high 
hepatobiliary clearance of BN-like peptides [60]. Sev-
eral new BN peptide derivatives with the low liver 
and intestinal uptake have been designed and devel-
oped [1, 10, 61]. A number of BN peptide analogs ra-
diolabeled with  99mTc,  68Ga,  111In,  64Cu,  18F and  177Lu 
have been prepared and investigated for targeting of 
BN  receptor-expressing  tumors  including  prostate 
and breast cancer and are summarized in Tables 5 and 
6. Among these analogs, BN peptide antagonists have 
also been developed in order to further validate the 
“shift” from agonists to antagonists [62-64]. The data 
suggest  that  the  GRP  antagonists  may  be  superior 
targeting agents to GRP receptor agonists, which in-
dicate a possible change of paradigm in the field of 
BN-like  peptides.  In  addition,  the  antagonists  have 
clearly less side-effects compared to the agonists. The 
encouraging results obtained with these radiolabeled 
BN analogs indicate that some of them may find ap-
plications in clinical oncology in the near future. 
 
 
Table 5. Radiolabeled bombesin peptide analogs. 
Radiopeptide   Major application  Reference 
111In-DTPA-GABA-[D-Tyr6-Gln7-Trp8-Ala9-Val10--Ala11-His12
-Thi13-Nle14-NH2  
BN(6-14) (BZH1) 
 Targeting of BN/GRP receptor subtypes expressing tumors in 
rats 
[126] 
 [111In/177Lu]-DOTA-GABA-[D-Tyr6-Gln7-Trp8-  
Ala9-Val10--Ala11-His12-Thi13-Nle14-NH2  
BN(6-14) (BZH2) 
 
 
 
[67Ga/177Lu]-DOTA-PEG4-BN(7-14) 
(DOTA-PESIN) 
 Imaging and therapy of BN/GRP receptor-positive PC-3 tu-
mors in mice 
[127] 
177Lu-DO3A-CH2CO-G-4-aminobenzoyl- 
Q-W-A-V-G-H-L-M-NH2 (177Lu-AMBA) 
 Imaging and therapy of GRP receptor-positive tumors in 
mouse models  
[128] 
177Lu-DOTA-8-Aoc-BBN(7-14)NH2 /  
64Cu- NOTA-8-Aoc-BBN(7-14)NH2 
 Targeting of BN/GRP receptor-positive PC-3 prostate cancer 
cells in mice 
[129, 130] 
111In-[DTPA-Pro1,Tyr4]BN   Targeting of androgen-dependent BN/GRP receptor in hu-
man prostate tumor xenografts 
[131] 
[111In-DTPA-ACMpip5,Tha6,βAla11,Tha13,Nle14]BN(5-14)   Imaging of BN/GRP receptor-expressing prostate cancer in 
PC-3 tumor-bearing mice 
[132] 
[64Cu-NO2A-8-Aoc-BBN(7-14)NH2]/ 
[64Cu-NO2A-(X)-BBN(7-14)NH2] 
 microPET imaging of GRP receptor-positive T47-D breast and 
PC-3 prostate cancer xenografts in mice 
[133] 
64Cu-CB-TE2A-8-AOC-BBN(7-14)NH2 
64Cu-DOTA-8-AOC-BBN(7-14)NH2 
 microPET/CT imaging of BB2 receptor-positive prostate 
tumor in nude mice  
[134] 
64Cu-DOTA-linker-BN(7-14) 
 
 
 microPET imaging of BN/GRP receptor-positive T47-D breast 
cancer in mice. 
 
[135] 
 
 
64Cu-SarAr-SA-AoC-GSG-BN(7-14)/ 
64Cu-SarAr-SA-AoC-BN(7-14) 
 
 Targeting of GRP receptor-expressing prostate cancer in mice 
bearing PC-3 xenografts using PET/CT. 
[136] 
 
111In/68Ga-RM2 
 
 SPECT/PET-based imaging of GRP receptor-positive PC-3 
and LNCaP tumor-bearing nude mice. 
[137] 
 
 
68Ga-AMBA   GRP receptor-based imaging of prostate cancer in mice bear-
ing human prostate VCaP xenografts. 
[138] 
GABA, γ-aminobutyric acid; PEG4, 15-amino-4,7,10,13-tetraoxapentadecanoic acid; X, 0, -Ala, 5-Ava, 8-Aoc, or 11-Aun; CB-TE2A, 
1,4,8,11-tetraazabicyclo[6.6.2]hexadecane-4,11-diacetic acid. linker, Aba, Ava, Ahx, Aoc, or Ado.; 8-Aoc, 8-aminooctanoic acid; GRP, gas-
trin-releasing peptide; Aca, aminocaproic acid; 8-Aoc, 8-aminooctanoic acid. 
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Table 6. Bombesin peptide analogs radiolabeled with F-18 and Tc-99m radionuclides.  
Radiopeptide   Major application 
 
Reference 
18F-FB-[Lys3]BBN/18F-FB-Aca-BBN(7-14) 
 
 microPET imaging of BN/GRP receptor-positive prostate 
cancer in nude mice 
[139] 
 
 
18F-BAY 86-4367 
  
 Detection of BN/GRP receptor-positive PC-3 xenografts 
using PET/CT. 
 
[140] 
 
99mTc(CO)3-BBS(7-14) 
 
 Targeting of BN/GRP receptor-positive PC-3 prostate 
cancer in nude mice 
 
 
[141] 
99mTc(CO)3-DTMA-(X)-BBN(7-14)NH2   Targeting of GRP receptor-positive prostate cancer in mice 
bearing PC-3 xenografs  
  
[142] 
99mTc-(CO)3-Lys-PEG-BN   Small-animal SPECT imaging of BN2/GRP recep-
tor-positive prostate cancers in nude mice with PC-3 tumor 
xenografts. 
 
[143] 
99mTc-(CO)3-X-Y-BN(7-14)NH2   Targeting of GRP receptor-positive T47-D breast cancer in 
xenografted SCID mice. 
 
[144] 
 FB, 4-Fluorobenzoyl; BBN, bombesin; GRP, gastrin-releasing peptide; Aca, aminocaproic acid; DTMA, 
2-(N,N'-Bis(tert-butoxycarbonyl)diethylenetriamine) acetic acid. 
 
 
 
Vasoactive intestinal peptide analogs 
Vasoactive intestinal peptide (VIP) is a 28-amino 
acid neuropeptide (Figure 3) with a broad range of 
biologic  activities.  In  addition  to  its  vasodilatory 
properties,  it  promotes  growth  and  proliferation  of 
normal and cancer cells mediated by cell-surface re-
ceptors [1, 2, 20]. The actions of VIP are mediated by 
two receptor subtypes (VPAC1 and VPAC2). Each of 
these receptor subtypes have different pharmacology 
and distributions, but VIP has high-affinity for both 
VIP receptor subtypes [65]. VIP is pharmacologically 
very potent molecule and doses in the submicrogram 
range will produce toxic effects thus requiring an ef-
ficient  purification  step  of  the  radiolabeled  peptide 
before administration in order to reduce the admin-
istration dose to subpharmacologic levels [6]. As with 
other  natural  peptides,  VIP  also  undergoes  rapid 
degradation  in vivo  with  a  half-life  less  than  1  min 
[66]. Thus, the development of synthetic VIP analogs 
that are metabolically stable and retain high affinity 
and  selectivity  for  VIP  receptors  or  a  VIP  receptor 
subtype  can  be  useful  for  targeting  VIP  recep-
tor-expressing tumors. A high number of VIP recep-
tors are expressed on various tumors, including neu-
roendocrine tumors, brain tumors, adenocarcinomas 
of the pancreas, prostate, breast, colon, stomach and 
liver  [2,  67].  Clinical  studies  of  VIP  analogs  radio-
labeled with 123I and 99mTc for scintigraphic imaging of 
VIP receptor-positive tumors (pancreatic adenocarci-
nomas,  endocrine  tumors,  colorectal  cancer,  etc.) 
demonstrate the usefulness of these radiolabeled VIP 
analogs [19-21]. Unfortunately, the overexpression of 
VIP receptors on  normal tissues, particularly in the 
lungs,  central  nervous  system,  liver,  intestine  etc., 
combined  with  the  complex  radiolabeling  protocol 
limit  the  widespread  clinical  application  of  radio-
labeled VIP analogs. 
Cholecystokinin/gastrin peptide analogs 
The peptides gastrin and cholecystokinin (CCK), 
which are highly expressed in the intestines and also 
in brain, exert their functions through interaction with 
two receptors, CCK2/gastrin and CCK1 receptors [2, 
26]. High expressions of CCK2/gastrin receptors are 
found  in  human  medullary  thyroid  cancer  (MTC), 
small cell lung cancer (SCLC), astrocytomas, stromal 
ovarian  cancer,  gastroenteropancreatic  NETs  and 
gastrointestinal stromal tumors [2, 67]. The peptides 
of the gastrin and CCK family are characterized by the 
C-terminal  amidated  receptor  binding  sequence 
Trp-Met-Asp-Phe-NH2.  It  has  been  shown  that  the Theranostics 2012, 2(5) 
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C-terminal octapeptide portion of CCK (Figure 3) has 
the  same  efficacy  and  potency  as  the  full  length 
33-amino acid residue peptide [2, 28]. The develop-
ment of radiolabeled CCK/gastrin peptide analogs is 
beneficial  for  targeting  the  CCK/gastrin  expressing 
tumors in vivo. In a recent study [27], the diagnostic 
and therapeutic value of three promising CCK-2 re-
ceptor-binding  peptides,  99mTc-N4-Gly-D-Glu- 
(Glu)5-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 
(99mTc-demogastrin  2),  111In-DOTA-D-Asp-Tyr-Nle- 
Gly-Trp-Nle-Asp-Phe-NH2  (111In-DOTA-CCK),  and 
111In-DOTA-D-Glu-Ala-Tyr-Gly-Trp-Met-Asp-Phe-N
H2  (111In-DOTA-MG11)  were  evaluated  in  patients 
with  MTCs.  The  results  of  this  study  suggest  that 
99mTc-demogastrin 2 showed better detectability and 
visualized more tumor lesions in patients than with 
111In-DOTA-CCK  and  111In-DOTA-MG11.  Also,  the 
uptake of the  111In-labeled peptides in patients with 
MTCs and metastases was found to be lower than that 
of  99mTc-demogastrin  2.  All  three  radiolabeled  pep-
tides showed comparable renal uptake profiles. These 
findings indicate the potential 99mTc-demogastrin 2 for 
targeting  of  the  CCK/gastrin  expressing  tumors  in 
patients and deserve further evaluation.  
DOTA-conjugates of MG11 have been developed 
by introducing hydrophilic but uncharged spacers of 
different lengths, such as PEG or D-amino acids (D-Ser 
or D-Gln) [29], where it was shown that the number of 
D-Gln  residues  played  an  important  role  and  the 
length of the spacer determined the metabolic stability 
as this was significantly improving from (D-Gln)2 to 
(D-Gln)6. Recently, several radiolabeled CCK/gastrin 
peptide  analogs  have  been  prepared  and  evaluated 
for  diagnostic  imaging  or  radionuclide  therapy  of 
CCK/gastrin  receptor-expressing  tumors.  Based  on 
side-by-side  comparative  studies  among  twelve 
DOTA-conjugated  analogs,  developed  by  different 
research groups, optimal peptide analogs were found 
to  be  the  linear  minigastrin  analog,  with  six  D-Glu 
residues  (PP-F11),  a  divalent  analog  (MGD5)  and  a 
cyclic peptide cyclo-MG1, combining the high tumor 
uptake with low kidney retention [68]. 
Neurotensin peptide analogs 
Neurotensin (NT) is a tridecapeptide (Figure 3) 
found  in  the  brain  and  gut  and  has  many  growth 
regulatory functions. The biological effects of NT are 
mediated  through  the  action  of  three  different  NT 
receptors: NTR1, NTR2 and NTR3 [2, 69]. The phar-
macological effects of NT initiated from the specific 
interaction of the peptide with cell-surface receptors. 
But the pharmacology and mode of action of NT re-
ceptors are not well understood [2]. NTR1 and NTR2 
belong to the family of G-protein-coupled receptors, 
whereas the NTR3 is a single transmembrane domain 
receptor and is similar to sortilin, a protein involved 
in receptor sorting [70]. Overexpression of NTR1 has 
been found in several human cancers including Ewing 
sarcomas, meningiomas, astrocytomas, medulloblas-
tomas and pancreatic carcinomas [2, 67]. Neurotensin 
is rapidly degraded in blood by endogenous pepti-
dases. Recently, different cleavage-sites in the natural 
sequence  have  been  identified  which  provided  the 
future direction for the development of metabolical-
ly-stable NT analogs [23]. Based on the favorable pre-
clinical  animal  studies,  one  of  the  99mTc-labeled  NT 
analogs,  [99mTc(CO)3](NαHis)Ac-Lys-(ψCH2-NH)- 
Arg-Pro-Tyr-Tle-Leu (99mTc-NT-XI), was evaluated for 
its tumor targeting characteristics in ductal pancreatic 
adenocarcinoma  patients  [22].  The  initial  clinical 
findings are not very favorable due to the high non-
specific uptake of radioactivity in the intestinal region 
and in the kidneys. More clinical data is required to 
determine the real potential of this radiolabeled pep-
tide as a tumor imaging agent. Some of the NT ana-
logs developed for targeting NT receptor-expressing 
tumors are summarized in Table 7. 
 
Alpha-melanocyte stimulating hormone 
peptide analogs 
In  recent  years,  alpha-melanocyte-stimulating 
hormone  (α-MSH)  peptide  analogs  were  prepared 
and evaluated for both melanoma imaging and radi-
otherapy [71-75]. Alpha-MSH is a 13-amino acid pep-
tide  (Ac-Ser1-Tyr2-Ser3-Met4-Glu5-His6-Phe7-Arg8- 
Trp9-Gly10-Lys11-Pro12-Val13-NH2)  and  is  mainly  re-
sponsible for the regulation of skin pigmentation [76]. 
Alpha-MSH  peptide  targets  the  α-MSH  receptor 
(melanocortin type 1 receptor (MC1R)). The MC1R is 
overexpressed in most murine and human melanoma 
metastases [2, 77], thus making it an attractive molec-
ular target for imaging and radiotherapy of melano-
mas. Recently, several α-MSH peptide analogs radio-
labeled with  99mTc [71],  64Cu [72],  68Ga [73],  18F [74], 
and  111In [71, 75] have been prepared and evaluated 
for melanoma targeting (see Table 7). In addition, an 
α-MSH analog, ReCCMSH(Arg11), radiolabeled with 
188Re has shown good therapeutic potential in animals 
[78]. The data demonstrates that radiolabeled α-MSH 
analogs are potential candidates for diagnostic imag-
ing or radiotherapy of melanoma tumors.  
 
 Theranostics 2012, 2(5) 
 
http://www.thno.org 
493 
Table 7. Tumor imaging peptide radiopharmaceuticals based on neurotensin or α-MSH. 
Radiopeptide   Major application 
 
Reference 
99mTc/188Re-NT-XIX   Imaging and therapy of NTR1-positive tumors in 
nude mice with HT-29 xenografts  
[23] 
[99mTc-N40,()Ala7,Dab9,XAA12] NT(7-13)   Imaging of NTR1-positive tumors in WiDr tu-
mor-bearing mice  
[25] 
[Cys3,4,10,D-Phe7,Arg11]α-MSH3-13 
(99mTc-(Arg11)CCMSH)/ 
[68Ga/111In]-DOTA-Re(Arg11)CCMSH 
 Targeting of primary and metastatic melanoma in 
B16/F1 melanoma-bearing mice 
[71, 78] 
64Cu-CBTE2A-ReCCMSH(Arg11)   microPET imaging of malignant melanoma in mice 
bearing B16/F1 melanoma tumor 
[72] 
[Ac-Nle4,Asp5,D-Phe5,Lys11(pz-99mTc(CO)3]--MSH4–11   Melanoma tumor targeting in melanoma-bearing 
C57BL6 mice 
[145] 
[111In/90Y/68Ga]-CHX-A″-Re(Arg11)CCSMSH    SPECT/PET imaging of melanoma tumors in B16/F1 
melanoma-bearing mice 
[73] 
Ac-Nle-Asp-His-D-Phe-Arg-Trp-Gly-Lys-NH2 
(18F-FB-NAPamide) 
 PET imaging of MC1R expression in melanoma xen-
ografted mouse models 
  
[74] 
NT, neurotensin; NTR1, neurotensin receptor 1; XAA, Ile or Tle. 
 
RGD peptides for targeting integrin αvβ3 ex-
pression  
In addition to target G-protein-coupled receptors 
on tumor cell membranes, there has been a growing 
interest in targeting integrin receptors for in vivo tu-
mor imaging [6, 79, 80]. The vitronectin receptor, αvβ3 
integrin receptor is known to play an important role 
in tumor-induced angiogenesis and tumor metastasis. 
This receptor is expressed on various malignant hu-
man  tumors  (ovarian,  breast,  neuroblastoma,  mela-
noma, etc.) and is highly expressed on activated en-
dothelial  cells  during  angiogenesis  [34,  81].  In  con-
trast, expression of αvβ3 is weak in resting endothelial 
cells and most normal tissues. The restricted expres-
sion of integrin αvβ3 during tumor growth, invasion 
and metastasis present an attractive molecular target 
for diagnosis and therapy of the rapidly growing and 
metastatic tumors [79]. The inhibition of αvβ3 is cur-
rently  being  evaluated  as  a  new  strategy  for  tu-
mor-specific anticancer therapy [34]. RGD family of 
peptides containing the RGD sequences preferentially 
bind to the αvβ3 integrin receptor have been used for 
noninvasive  imaging  of  the  integrin  αvβ3-positive 
tumors  by  SPECT  and  PET.  A  number  of  synthetic 
peptides  containing  the  RGD  sequences  have  been 
radiolabeled with 99mTc, 111In, 123I, 68Ga, 64Cu, 18F and 
90Y and evaluated for their ability to target the αvβ3 
receptor (see Table 8). Most of them showed in vitro 
affinity  for  αvβ3  and  allowed  targeting  of  recep-
tor-positive  tumors  in  vivo.  However,  major  differ-
ences were found in the pharmacokinetic profiles of 
different radiolabeled RGD peptide analogs [34-37, 79, 
82-92].  One  of  the  peptide  tested  clinically  is 
[18F]Galacto-RGD, a glycosylated cyclic pentapeptide, 
which  demonstrated  noninvasive  quantitative  as-
sessment  of  the  αvβ3 expression  pattern  in  patients 
with malignant tumors [34, 80]. However, the facile 
preparation of labeled RGD with radiometals, such as 
68Ga-NODAGA-c(RGDfK)  makes  it  an  attractive  al-
ternative  to  18F-labelled  RGD  peptides.  Moreover, 
NODAGA has as well been used for radiolabeling of 
RGD  with  64Cu  showing  improved  characteristics 
compared  to  the  corresponding 
64Cu-DOTA-c(RGDfK) [36].  
In  a  recent  study,  a  RGD–SST  hybrid  peptide, 
RGD-DTPA-octreotate  [c(Arg-Gly-Asp-D-Tyr-Asp)- 
Lys(DTPA)-D-Phe-c(Cys-Tyr-D-Trp-Lys-Thr-Cys)-Thr
],  composed  of  the  SST  receptor-targeting  peptide, 
Tyr3-octreotate  peptide  [D-Phe-c(Cys-Tyr-D-Trp-Lys- 
Thr-Cys)-Thr],  the  DTPA  chelator  and  the  apopto-
sis-inducing RGD peptide sequence was evaluated for 
targeting  SST  and  αvβ3-receptor-positive  tumors.  In 
rats  bearing  CA20948  rat  pancreatic  tumors, 
RGD-111In-DTPA-octreotate  showed  a  high  tumor 
uptake and retention. A significantly high renal up-
take  was  observed  in  rats  making  this  peptide  un-
suitable  for  radiotherapy.  The  results  highlight  the 
benefit of using RGD–SST hybrid peptide for target-
ing  of  tumors  [79,  82].  It  was  also  found  that  the 
111In-labeled  hybrid  peptide,  RGD-DTPA-octreotate, 
is more powerful in promoting apoptosis than the two 
monopeptides (the RGD and octreotate), thus the hy-
brid peptide can greatly improve the therapeutic ef-
ficacy of SST peptide analogs [82, 83]. 
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Table 8. RGD peptide-based radiopharmaceuticals. 
Radiopeptide   Major application 
 
Reference 
Cyclo(RGDfK(DOTA)) 
[68Ga/111In-DOTA-RGD]  
 
 Targeting of αvβ3-positive human melanoma M21 tumor cells 
in nude mice 
  
[35] 
 c(RGDyK), (68Ga-NOTA-RGD1) 
 E[c(RGDyK)]2, (68Ga-NOTA-RGD2) 
E{E[c(RGDyK]2}2 (68Ga-NOTA-RGD4) 
 
 microPET imaging of integrin αvβ3 expression in nude mice 
bearing U87MG human glioblastoma xenografts 
  
[85] 
PEG4-E[PEG4-c(RGDfK)]2, P-PRGD2) 
(18F-FP-P-PRGD2) 
 
 Imaging of tumor angiogenesis in nude mice bearing 
αvβ3-positive tumors  
 
[86] 
 
64Cu-DOTA-E{E[c(RGDfK)]2}2 
 
 microPET imaging of glioma integrin αvβ3 expression in mice 
with glioma xenografts  
 
[87] 
64Cu-CB-TE2A-c(RGDyK) 
64Cu-diamsar-c(RGDfD) 
 Targeting of tumor angiogenesis in nude mice with 
αvβ3-positive M21melanoma 
[146] 
[111In]-DOTA-E-[c(RGDfk)]2 
[111In]-DOTA-PEG4-E-[c(RGDfk)]2 
[111In]-DOTA-E-E-[c(RGDfK)]2 
[111In]-DOTA-K-E-[c(RGDfK)]2 
 
 Targeting of αvβ3-expressing tumors in mice carrying 
SK-RC-52 cells 
  
  
[88] 
111In-DOTA-E-c(RGDfK)   αvβ3 integrin-targeting in mice with OVCAR-3 human ovarian 
carcinoma cells 
 
[89] 
[111In/90Y]-DOTA-E-[c(RGDfK)]2   Diagnosis/therapy of αvβ3-expressing tumors in mice bearing 
αvβ3-positive OVCAR-3 cells  
  
[90] 
111In-DOTA-E-c(RGDfK) 
111In-DOTA-E-[c(RGDfK)]2 
111In-DOTA-E-{E[c(RGDfK)]2}2 
 
 Targeting of αvβ3 inegrin expression in mice with SK-RC-52 
xenografts  
 
 
[37] 
 
68Ga-NOTA-E[PEG4-c(RGDfK)]2 
68Ga-NOTA-E[Gly3-c(RGDfK)]2 
 microPET imaging of integrin αvβ3 expression in U87MG 
tumor xenograft models  
  
[91] 
68Ga/64Cu-NODAGA-c(RGDfK) 
 
 microPET imaging of integrin αvβ3 expression in U87MG 
tumor xenograft models  
 
[36]  
[99mTc]HYNIC-RGD 
 
 Imaging integrin αvβ3 expression in nude mice bearing M21, 
M21L melanoma and A549 small cell lung tumor cells  
 
[92] 
99mTc-HPMA-RGD4C-DPK   Targeting tumor angiogenesis in mice bearing DU145 or PC-3 
prostate tumor xenografts 
 
[147] 
99mTcO(MAG2-3G3-dimer)   Imaging of tumor integrin αvβ3 expression in nude mice 
bearing U87MG xenografts  
 
[148] 
RGD, Arg-Gly-Asp; DOTA, 1,4,7,10-tetraazadodecane-N,N',N'', N'''-tetraacetic acid; PEG4, 15-amino-4,7,10,13-tetraoxapentadecanoic acid; 
NOTA, 1,4,7-triazacyclononane-1,4,7-triacetic acid; 18F-FP, 4-nitrophenyl 2-18F-fluoropropionate; HPMA, 
N-(2-hydroxypropyl)methacrylamide). 
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To  find  out  whether  dual  receptor-targeting  is 
advantageous  over  a  single  receptor-binding  probe, 
recently BBN–RGD hybrid peptide was evaluated for 
its ability to target an androgen-independent prostate 
cancer cell line (PC-3), which expresses receptors for 
both  GRP  and  integrin  αvβ3  [84].  A  heterodimer 
BBN–RGD conjugate, that binds to both GRP and in-
tegrin αvβ3 receptor, was synthesized by coupling the 
cyclic  RGD  peptide  c(RGDyK)  with  BBN(7-14) 
through a glutamate linker and then labeled with 18F. 
The dual receptor-targeting (GRP and integrin αvβ3) 
study showed the significantly higher tumor targeting 
and  better  pharmacokinetic  characteristics  of 
18F-BBN-RGD  as  compared  to  the  corresponding 
monomeric 18F-BBN and 18F-RGD analogs. Thus, there 
is a need to develop heterodimeric ligands for efficient 
targeting of multiple-receptor systems and this inter-
esting approach should also be tested on other pep-
tide receptor systems. Based on the RGD peptide se-
quence, a number of small cyclic peptides that possess 
high and specific affinity for the αvβ3 integrin have 
been  synthesized  and  radiolabeled  with 
SPECT/PET-based  radionuclides  (see  Table  8).  The 
abilities  of  these  peptides  to  target  αvβ3-expressing 
tumors have made radiolabeled cyclic RGD peptides 
powerful  tools  for  diagnostic  imaging  and  targeted 
therapy of αvβ3-expressing tumors. 
Exendin peptide analogs 
The Glucagone-like peptide receptor (GLP-1R) is 
a  member  of  the  G-protein-coupled  receptor  family 
and is mainly expressed in the pancreatic islet cells, 
the intestine, lung, kidney, breast and the brainstem. 
GLP-1R were found to be overexpressed in insulino-
mas, an usually benign insulin secreting neuroendo-
crine tumor of the pancreas [53]. The natural ligand 
GLP-1 consists of 30-amino acids and has a half-life of 
<2 min. Exendin-4 and Exendin-3 are two 39-amino 
acid  natural  peptides  which  are  metabolically  re-
sistant and share nearly 50% homology with the hu-
man GLP-1. Exendin-4 and Exendin-3 differ by only 
two amino acid residues near the amino terminus.  
Exendin-4 has been radiolabeled with  111In ini-
tially  using  DTPA  coupled  to  Lys40  side-chain  with 
aminohexanoic  acid  (Ahx)  as  a  spacer 
([Lys40(Ahx-DTPA)NH2]-exendin-4)  [30,  31]. 
111In-DTPA-exendin-4 was evaluated for its therapeu-
tic efficiency, based on the the Auger electrons of 111In 
in  tumor  bearing  transgenic  Rip1Tag2  mice  [93]. 
Clinically,  111In-DTPA-exendin-4  scans  were  able  to 
distinguish between benign and malignant insulino-
mas [94]. Recently, 111In-DTPA-exendin-4 was used to 
follow β-cell viability of an islet transplantation into 
the forearm of a human patient, where one year after 
the transplantation, focal accumulation of the tracer 
was observed in planar images [95]. The correspond-
ing  111In-DOTA-exendin-4  conjugate  has  also  been 
used in  patients with very promising results in the 
localization of insulinomas and detection of pancre-
atic and ectopic insulinomas [96, 97]. Exendin-4 and 
exendin-3 have been radiolabeled with 99mTc and 68Ga 
[32, 33]. Among these tracers, 99mTc-labeled exendin-4 
had the lowest estimated effective dose and it is cur-
rently under clinical evaluation [98, 99].  
Receptor-mediated radionuclide therapy with 
peptide radiopharmaceuticals 
Receptor-binding  peptides  radiolabeled  with 
diagnostic radionuclides can be used for identification 
of receptor-positive tumor lesions, treatment planning 
and dosimetry. When labeled with a therapeutic ra-
dionuclide, the same peptide can be utilized for tar-
geted radionuclide therapy [9-14]. Typically, peptide 
receptor radionuclide therapy carried out with a pep-
tide labeled with a therapeutic radionuclide, able to 
bind specifically to the target receptor on tumor cells 
and be able to deliver an effective radiation dose to 
the tumor cells with minimal damage to normal tis-
sues. The success of this approach depends upon the 
amount  of  radioligand  accumulated  within  tumor 
cells and the rates of internalization, degradation and 
recycling of both radioligand and receptor. The loca-
tion  and  the  size  of  tumor/tumor  type  are  the  im-
portant  factors  to  be  considered  for  effective  radio-
therapy.  The  in vivo  stability  and  construction  of  a 
peptide radiopharmaceutical is crucial as it may in-
fluence tumor uptake, retention, and clearance via the 
renal  pathway  [100].  The  radionuclide’s  physical 
properties, such as the type of radiation emitted, the 
emission energies, the distance over which the energy 
is deposited, and the physical half-life of the radionu-
clide are important. Some of the therapeutic radionu-
clides used for labeling peptides include yttrium-90 
(90Y)  and  lutetium-177  (177Lu).  Both  are  -particle 
emitters; 90Y has a maximum energy of 2.3 MeV and a 
maximum range of 12 mm in tissue and  177Lu has a 
maximum energy of 0.5 MeV and a maximum tissue 
range of approximately 2 mm [13, 14, 101]. Lu-177 is 
also  a  γ-emitter,  which  enables  γ-scintigraphy  and 
thus  facilitates  dosimetry  and  disease  staging.  A 
low-energy  -emitter,  such  as  177Lu,  with  a  shorter 
range is more appropriate for smaller tumors or me-
tastases while the high-energy -emitter such as 90Y is 
suited for larger tumors, with a heterogenous receptor 
distribution [11, 13, 51, 101, 102]. The selection of a 
radionuclide  for  therapy  is  thus  dependent  on  the 
potential  clinical  applications  and  on  the  chemistry 
and  physical  properties  of  the  therapeutic  radionu-Theranostics 2012, 2(5) 
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clide [103]. Indeed, it has been shown that the com-
bination  of  radionuclides  with  different  -energies 
and particle ranges can achieve higher cure rates in 
tumors of different sizes. Clinical trials are underway 
to support the experimental findings.  
A number of radiolabeled SST peptide analogs 
are currently in use to treat patients with SST recep-
tor-expressing tumors. These conjugates consist of a 
SST  peptide  analog  (i.e.  octreotide  or  octreotate),  a 
chelating  moiety  (i.e.  DOTA)  and,  a  therapeutic  ra-
dionuclide (i.e.  90Y or  177Lu). The chelator, which is 
linked to the SST peptide analog, forms a stable com-
plex with the radionuclide. The basic principle of tu-
mor-targeting  after  systemic  administration  of  the 
peptide involves binding to the SST receptors, which 
are  overexpressed  on  the  cell  surface  of  the  tumor 
cells,  followed  by  internalization  of  the  radionu-
clide-peptide complex into the tumor cells. The emit-
ted radiation can damage the DNA, which may cause 
the cell death. In clinical practice, different combina-
tions  of  radionuclides  and  SST  peptide  analogs  are 
used in order to achieve optimal targeting of SST re-
ceptor-positive  tumors.  These  analogs  differ  from 
each other in their affinity profiles for the various SST 
receptor types. This variable receptor affinity is im-
portant because it can greatly affect the clinical use-
fulness of radiolabeled SST peptide analogs. The de-
velopment  of  a  “universal  SST  ligand”  capable  of 
targeting multireceptor system will be advantageous 
for the efficient targeting of SST receptor-expressing 
tumors  having  different  SST  receptor  types.  The 
commonly  available  radionuclides  and  SST  peptide 
analogs are described briefly in the following sections. 
Somatostatin receptor radiotherapy with 
111In-DTPA0-octreotide (111In-OctreoScan) 
After the successful use of radiolabeled SST an-
alogs (e.g., 111In-OctreoScan) for the diagnosis of SST 
receptor-expressing  tumors  in  clinical  practice,  the 
next  rational  step  was  to  label  these  peptides  with 
therapeutic radionuclides  (emitting α- or -particles 
or Auger or conversion electrons) [104] and to carry 
out  radionuclide  therapy  with  these  radiopeptides. 
Initial therapeutic studies were performed with high 
radioactivity doses of  111In-DTPA0-octreotide (which 
emits  Auger  and  internal  conversion  electrons  that 
exert an anti-proliferative effect in malignant tumors) 
in patients with metastatic NETs, have been associ-
ated with significant symptomatic improvement but 
relatively  few  and  short-lived  objective  tumor  re-
sponses  [11].  Despite  encouraging  results  with  sub-
stantial  symptomatic  improvement  in  the  patients, 
111In-coupled peptides are not ideal for radiotherapy 
because  of  their  small  particle  range,  short  tissue 
penetration (~10 μm) and radiotoxicity [11, 105]. 
 To  develop  a  more  effective  radiotherapeutic 
peptide, DTPA0-D-Phe1-octreotide (OctreoScan) (Fig-
ure 1) was modified by replacing Phe3 with Tyr3 in the 
octapeptide  sequence  to  increase  its  hydrophilicity 
and  to  improve  its  affinity  for  sst2  as  compared  to 
octreotide and the DTPA chelator was replaced with 
DOTA (Figure 2) [1, 2, 53], in order to improve radi-
onuclide-chelator complex stability for peptides radi-
olabeled  with  more  effectual  therapeutic  radionu-
clides, such as 90Y and 177Lu. The macrocyclic chelator 
DOTA-linked SST peptide analogs can also be radio-
labeled  stably  with  111In,  making  them  suitable  for 
both diagnosis and radiotherapy [9, 10]. Peptides ra-
diolabeled with -emitting radionuclides (90Y or 177Lu) 
are preferred for radionuclide therapy since the parti-
cles  they  emit  have  sufficient  energy  to  cause  cell 
damage without penetrating very far into surround-
ing tissue [11]. This underlines the importance of the 
radiometal used for radiolabeling of peptides (see the 
following sections), and its influence on the pharma-
cokinetic and tumor targeting characteristics [103].  
Somatostatin receptor radiotherapy with 
[90Y-DOTA0,Tyr3]octreotide 
(90Y-DOTA-TOC) 
Somatostatin  receptor  binding  peptides  radio-
labeled  with  -emitters  have  superior  therapeutic 
potential since a high-energy -emitter (e.g.  90Y) at-
tached to a SST peptide analog can potentially deliver 
a  high  radiation  dose  specifically  to  SST  recep-
tor-expressing  tumor  cells.  The  same  SST  analog 
(D-Phe1,  Tyr3-octreotide),  was  coupled  with  DOTA 
(instead of DTPA) (Figure 2), for complexing with 90Y 
for  radiotherapy  application.  Targeted  radionuclide 
therapy  studies  conducted  in  different  institutions 
with this SST peptide analog (90Y-DOTA-TOC or Oc-
treoTher) [8, 44, 106-108] showed complete or partial 
remissions  (10–34%)  in  patients  with  NETs.  These 
ranges  were  higher  than  those  obtained  with 
111In-DTPA0-octreotide.  In  the  most  recent  clinical 
study  [44],  the  outcome  of  90Y-DOTA-TOC  therapy 
(i.e. response, survival, and safety profile) was inves-
tigated in a large cohort of patients with a wide spec-
trum of NETs. This study documents the long-term 
outcome  of  90Y-DOTA-TOC  treatment  in  patients; 
response to  90Y-DOTA-TOC was found to be associ-
ated  with  longer  survival.  SST  receptor  imaging  is 
found  to  be  predictive  for  both  survivals  after 
90Y-DOTA-TOC  treatment  and  occurrence  of  renal 
toxicity. The high tumor uptake in the pretherapeutic 
diagnostic scan with [111In-DTPA]octreotide was sig-
nificantly associated and predictive of longer survival 
whereas  high  kidney  uptake  in  the  diagnostic  scan Theranostics 2012, 2(5) 
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predicted the risk of severe kidney toxicity.  
Somatostatin receptor radiotherapy with 
[177Lu-DOTA0,Tyr3]octreotate (DOTA-TATE) 
Another SST peptide analog, Tyr3-octreotate, in 
which the C-terminal Thr(ol) (threoninol), as used in 
octreotide, is replaced with the natural amino acid Thr 
(threonine) (Figure 2), is shown to have significantly 
higher  affinity  for  the  sst2  compared  with 
[DOTA0,Tyr3]octreotide  in  in vitro  investigation  [52, 
109].  Targeted  radionuclide  therapy  with 
177Lu-DOTA-TATE  [102,  105,  110,  111]  showed  an 
overall  response  of  30-38%  and  a  significantly  high 
median  overall  survival  of  48  months  has  been  re-
ported.  It  was  observed  that  the  quality  of  life  im-
proved  significantly  after  treatment  with 
177Lu-DOTA-TATE [111].  
The kidney is the dose-limiting  organ  in these 
peptide  receptor  radionuclide  studies,  as  the  small 
peptides are generally reabsorbed and retained in the 
negatively  charged  proximal  tubule  cells  after  glo-
merular filtration. In order to reduce the uptake of a 
radiopeptide in the kidney, infusions containing pos-
itively charged lysine and arginine are used during 
therapy [44, 45, 102]. A recent study regarding long 
term  renal  toxicity  after  different  doses  of 
177Lu-DOTA-TATE together with the effects of dose 
fractionation  and  lysine  co-injection  in  two  tu-
mor-bearing  rat  models  [112]  revealed  that  the  ad-
ministration of high doses of  177Lu-DOTA-TATE re-
sulted in severe renal damage in rats. The data con-
firms  that  the  fractionation  of  doses  together  with 
co-injection  of  lysine  has  beneficial  effects  in  pre-
venting the kidney damage.  
The  overall  results  obtained  with 
90Y-DOTA-TOC and 177Lu-DOTA-TATE is impressive 
in terms tumor regression. It has been shown that by 
using the proper kidney protection procedures during 
radionuclide therapy, renal toxicity can be minimized.  
Combination radionuclide therapy with 
90Y-DOTA-TOC and 177Lu-DOTA-TATE 
In order to treat patients with tumors of different 
sizes  and  of  non-homogenous  receptor  distribution, 
the “combination radiotherapy” using a high-energy 
β-emitter  90Y  for  larger  tumor  lesions  and  the 
low-energy  β-emitter  177Lu  for  smaller  lesions  and 
metastases  seems  to  be  an  attractive  approach  [11, 
101]. Animal studies have shown this combination of 
different radionuclides (90Y and  177Lu) provides dif-
ferent  -energies  and  particle  ranges  and  achieves 
higher cure rates in tumors of various sizes than either 
radionuclide  alone  [11].  It  has  been  shown  that  tu-
mor-bearing  rats  treated  with  a  combination  of 
90Y-DOTA-TOC  and  177Lu-DOTA-TATE  1:1  have 
longer survival than those treated with either 100% 
90Y-DOTA-TOC  or  177Lu-DOTA-TATE  conjugate 
alone [14, 101]. These results highlight the benefit of 
using  combination  of  radionuclides  with  different 
energies  and  particle  ranges  to  achieve  maximum 
therapeutic effects.  
Recently,  a  combined  protocol  was  applied  by 
Kunikowska et al. [113] in 50 patients with dissemi-
nated NETs in a prospective study, where one group 
(A)  was  treated  with  90Y-DOTA-TATE,  the  second 
group  (B)  received  1:1  90Y/177Lu-DOTA-TATE.  The 
median  survival  time  in  group  A  was  26.2  months 
while in group B it was not reached during the ob-
servation period (54 months). Median event-free sur-
vival was also superior in group B (29.4 months) vs. 
group A (21.4 months). The safety of both protocols 
was comparable and the side effects were mild and 
rare. 
Conclusions 
Peptides  are  important  biological  tools  in  the 
fight  against  cancer.  The  importance  of  peptides  is 
due to the overexpression of their receptors in many 
human cancers that can be effectively targeted using 
these biological targeting vectors. In addition to their 
diagnostic value, radiolabeled peptides have shown 
enormous strength in targeted radionuclide therapy. 
The peptides are used as transport vehicles to guide 
the radionuclides to the tissues expressing a particular 
receptor.  The  effectiveness  of  radionuclide  therapy 
can be greatly enhanced when performed in combi-
nations  of  different  peptides  (peptides  cocktail)  or 
radionuclides, possibly because of more homogenous 
receptor targeting.  
The  presence  of  multiple  peptide  receptors  in 
selected  cancers  can  be  the  basis  for  multireceptor 
targeting using two or more radiopeptides in parallel. 
The  co-expression  of  multiple  receptors  in  human 
tumors appears to be a distinct feature of peptide re-
ceptors. Many of the peptide receptors exist as multi-
ple  subtypes.  A  major  challenge  is  to  take  full  ad-
vantage of the co-expression of peptide receptors for 
multireceptor tumor targeting. With rapid advance-
ment  in  technology,  it  is  possible  to  identify  the 
presence of new peptide receptor types/subtypes for 
efficient  tumor  targeting  in  order  to  obtain  a  more 
efficient and powerful means of diagnosis and ther-
apy. 
Despite the availability of an FDA-approved SST 
peptide analog,  111In-DTPA0-octreotide, potential im-
provements in the field of SST receptor targeting are 
still necessary. One important step would be the de-
velopment  of  SST  analogs  having  broader  affinity Theranostics 2012, 2(5) 
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profiles for SST receptor types, which may enhance 
the tumor uptake characteristic due to the presence of 
several receptor subtypes on the same tumor cell but 
also  on  the  development  of  antagonistic  peptides, 
based on the most recent findings.  
In spite of the remarkable advancements in the 
field of small peptides as targeting agents, there is a 
need  to  find  new  peptide  receptors  overexpressed 
(i.e., suitable peptide targets) preferentially on com-
mon human cancers (breast and prostate, etc.), and to 
develop  appropriate  radiolabeled  peptides  for  re-
spective targets. More important, is the development 
of peptide-based therapeutic compounds capable of 
obtaining regulatory approval.  
An upcoming challenge is the transfer from pre-
clinical animal trials to clinical human trials. With the 
commitments  of  different  disciplines  and  support 
from the industries, it is possible to translate preclin-
ical research into clinical settings. The application of 
small peptides will continue to expand as new dis-
coveries are made. 
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